Edition:
United Kingdom

Infant Bacterial Therapeutics AB (IBTb.ST)

IBTb.ST on Stockholm Stock Exchange

181.00SEK
21 Mar 2019
Change (% chg)

-- (--)
Prev Close
181.00kr
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
19,289
52-wk High
207.00kr
52-wk Low
110.50kr

Summary

Name Age Since Current Position

Peter Rothschild

68 Chairman of the Board

Staffan Stromberg

49 Chief Executive Officer

Daniel Mackey

2017 Chief Financial Officer

Anders Kronstrom

Chief Technical Officer

Eamonn Connolly

59 Head of Research & Development

Leif Gallo

General Counsel

Michael Owens

60 2017 Financial Controller

Sanjiv Sharma

Chief Commercial Officer

Paul Alhadeff

Head of Pharmaceutical Development and Manufacturing

Jin-Yu Lu

Project Coordinator

Christine Nguy

Business Development Analyst

Anders Ekblom

63 Director

Margareta Hagman

52 Director

Eva Iden

48 Director

Anthon Jahreskog

38 2018 Director

Lilian Henningson Wikstrom

57 2018 Independent Director

Kristina Sjoblom Nygren

57 2018 Independent Director

Biographies

Name Description

Peter Rothschild

Mr. Peter Rothschild serves as Chairman of the Board at Infant Bacterial Therapeutics AB. Peter Rothschild is Group President and founder of BioGaia together with Jan Annwall. Peter is an experienced entrepreneur and successful businessman. He guided BioGaia’s establishment and successful development as Managing Director of BioGaia for 19 years. Peter is also Chairman of the board of directors of several companies including TwoPac AB and MetaboGen AB. He holds Master of Business Administration degree.

Staffan Stromberg

Mr. Staffan Stromberg, Ph.D. serves as Chief Executive Officer at Infant Bacterial Therapeutics AB. Staffan has over 18 years of experience in the pharmaceutical industry. Besides his role as Head of Medical Devices at the Swedish Medical Products Agency, he has also been Vice President of Nicox France, and had management positions at AstraZeneca. Staffan has particularly experience in the development of orphan drugs as he was Head of R&D of Swedish Orphan.

Daniel Mackey

Mr. Daniel Mackey has been appointed Chief Financial Officer at Infant Bacterial Therapeutics AB effective as of January 2017. Daniel has 20 years experience from diverse U.S. and international management positions in finance and accounting with Investors Bank & Trust Co., Nordea Investment Management AB and Nordea Bank AB.

Anders Kronstrom

Mr. Anders Kronstrom serves as Chief Technical Officer at Infant Bacterial Therapeutics AB. Anders has an extensive experience in the pharmaceutical industry with specialization on pharmaceutical development, project leadership and business development. He holds Master of Science and Master of Business Administration degrees.

Eamonn Connolly

Mr. Eamonn Connolly, Ph.D. serves as Head of Research & Development at Infant Bacterial Therapeutics AB. Eamonn is the former VP Research of BioGaia, with 15 years experience working with pre-clinical and clinical research on live bacterial therapies. He has earlier experience from the pharmaceutical industry including leading positions in R&D at Kabi Vitrum, Pharmacia & Upjohn and Fresenius Kabi.

Leif Gallo

Mr. Leif Gallo serves as General Counsel at Infant Bacterial Therapeutics AB. Leif has extensive experience in the pharmaceutical industry as in-house counsel with global and managerial responsibilities (AstraZeneca, Orexo). He holds Master of Legal Letters degree.

Michael Owens

Mr. Michael Owens has been appointed Financial Controller at Infant Bacterial Therapeutics AB effective as of January 2017. He no longer serves as Chief Financial Officer at the Company effective as of January 2017. Michael has a background as Auditor at Arthur Andersen & Co. and Ernst & Young AB. He has held the position as CFO at Vitamex AB and as Financial Controller at Karolinska Development AB. Michael has 30+ years experience of finance of which two decades in the Nutritional Supplements and early stage Life Science industries. He holds Bachelor of Science degree in Business Administration.

Sanjiv Sharma

Mr. Sanjiv Sharma serves as Chief Commercial Officer at Infant Bacterial Therapeutics AB. Sanjiv has a blend of experience in large, mid-size and start-up companies in North America and Asia, with national and global responsibility for companies like Sanofi, Valeant, and start-ups – NicOx and Duchesnay USA. He holds Master of Business Administration degree.

Paul Alhadeff

Mr. Paul Alhadeff serves as Head of Pharmaceutical Development and Manufacturing at Infant Bacterial Therapeutics AB. Paul has more than two decades of experience in pharmaceutical development starting at Kabi Vitrum in 1989. During his career at AstraZeneca he has worked to bring several new drugs to the market, including Oxeeze Turbohaler and Symbicort. He holds Bachelor of Science degree.

Jin-Yu Lu

Ms. Jin-Yu Lu serves as Project Coordinator at Infant Bacterial Therapeutics AB. Jin has education in life science and bioentrepreneurship. She has experience in administrative and operational support for R&D projects. She holds Master of Science degree.

Christine Nguy

Ms. Christine Nguy serves as Business Development Analyst at Infant Bacterial Therapeutics AB. Christine is a trained pharmacist specialized in industrial pharmacy with education and experience in bioentrepreneurship. She holds a degree in Pharmacy and a Master of Science degree.

Anders Ekblom

Mr. Anders Ekblom serves as Director of Infant Bacterial Therapeutics AB. Anders Ekblom has extensive experience as an executive and leader with broad business knowledge from senior roles in the biopharmaceutical industry. During 19 years at AstraZeneca, Anders was a member of global executive teams holding different senior roles including Executive Vice President Global Medicines Development, and CEO AstraZeneca AB Sweden. He is currently Chairman of the Board at the Karolinska University Hospital. He holds Medical Doctor degree, Doctorate in Philosophy degree and is Associate Professor.

Margareta Hagman

Ms. Margareta Hagman serves as Director of Infant Bacterial Therapeutics AB. Margareta Hagman is working as CFO and Executive Vice President at BioGaia AB. Margareta has been at BioGaia since 1996 and in current position since 2010 and has broad experience in accounting, finance and investor relations. She holds Master of Business Administration degree.

Eva Iden

Anthon Jahreskog

Lilian Henningson Wikstrom

Ms. Lilian Henningson Wikstrom has been Independent Director of Infant Bacterial Therapeutics AB since May 15, 2018. She holds a Master of Science from Abo Akademi University and is a Doctor of Medical Sciences from Karolinska Institutet. Since 2010 she has been CEO of Karolinska Institutet Innovations AB in Solna. She has, in addition to being a PhD at the Ludwig Institute for Cancer Research in Stockholm, been active in the pharmaceutical industry, among other positions has been research director at NeuroNova AB.

Kristina Sjoblom Nygren

Ms. Kristina Sjoblom Nygren, M.D. has been Independent Director of Infant Bacterial Therapeutics AB since May 15, 2018. She has received a Doctor of Medical Sciences from Karolinska Institutet and is a licensed physician. She has been Chief Medical Officer, Head of Development, since 2018 at Santhera Pharmaceuticals in Basel, Switzerland. Kristina Sjoblom Nygren has extensive experience from the pharmaceutical industry, where she has held among other positions Head of Clinical Development at SOBI.